MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.71
0.00
0.00%
Opening 14:36 05/17 EDT
OPEN
7.01
PREV CLOSE
6.71
HIGH
7.21
LOW
6.70
VOLUME
306.92K
TURNOVER
1.27M
52 WEEK HIGH
51.21
52 WEEK LOW
6.26
MARKET CAP
327.43M
P/E (TTM)
-3.3644
1D
5D
1M
3M
1Y
5Y
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers
C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.
Benzinga · 1d ago
C4 Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Evaluating CFT8634, An Orally Bioavailable BiDAC Degrader For The Treatment Of Synovial Sarcoma And SMARCB1-Null Tumors
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how
Benzinga · 1d ago
BRIEF-C4 Therapeutics Announces First Patient Dosed In Phase 1/2 Trial Of CFT8634 For Treatment Of Synovial Sarcoma And Smarcb1-Null Tumors
reuters.com · 1d ago
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines an...
GlobeNewswire · 1d ago
C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT Newswires · 1d ago
HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy Rating
MT Newswires · 05/09 07:19
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 13:15
C4 Therapeutics: Q1 Earnings Insights
  C4 Therapeutics (NASDAQ:CCCC) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:11
More
No Data
Learn about the latest financial forecast of CCCC. Analyze the recent business situations of C4 Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
50.00%Buy
25.00%Hold
8.33%Under-perform
0.00%Sell
Analyst Price Target
The average CCCC stock price target is 29.64 with a high estimate of 84.00 and a low estimate of 10.00.
High84.00
Average29.64
Low10.00
Current 6.77
EPS
Actual
Estimate
-0.55-0.41-0.28-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 121
Institutional Holdings: 37.14M
% Owned: 76.11%
Shares Outstanding: 48.80M
TypeInstitutionsShares
Increased
41
2.43M
New
20
1.04M
Decreased
33
1.65M
Sold Out
16
457.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.53%
Pharmaceuticals & Medical Research
+0.95%
Key Executives
Chairman/Co-Founder/Executive Director
Marc Cohen
President/Chief Executive Officer/Director
Andrew Hirsch
Chief Financial Officer/Treasurer
Lauren White
Chief Scientific Officer
Stewart Fisher
Other
Adam Crystal
Secretary
Jolie Siegel
Director
Utpal Koppikar
Independent Director
Kenneth Anderson
Independent Director
Alain Cohen
Independent Director
Bruce Downey
Independent Director
Glenn Dubin
Independent Director
Malcolm Salter
No Data
No Data
About CCCC
C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

Webull offers kinds of C4 Therapeutics Inc stock information, including NASDAQ:CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.